CRCamilla Moreira Ribeiro

Camilla Moreira Ribeiro

*This is an algorithmically generated author record based on publicly available information.

Camilla Moreira Ribeiro has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gestrinone Subdermal Bioabsorbable Implant for the Treatment of Endometriosis-Associated Pelvic Pain: A Phase II, Safety Randomised Clinical Trial

    by Andre Luiz Malavasi Longo de Oliveira, Camilla Moreira Ribeiro, Eduardo Ramacciotti, See Pdf

    Background: Current treatments for endometriosis are limited, and gestrinone has emerged as a promising therapy. This study was designed to assess the safety of a subdermal bioabsorbable implant of gestrinone (85 mg) compared with placebo, in combination with the Levonorgestrel-Releasing Intrauterine System. Methods: This was a multicentre, double-blind, placebo-controlled trial conducted across seven Brazilian research centres. Participants with endometriosis underwent insertion of a levonorgestrel-releasing intrauterine system and were randomised 1:1 to receive either a subdermal bioabsorbable implant of gestrinone (85 mg) or a placebo. The primary safety outcome was the number of treatment-related serious adverse events over 24 weeks. The key secondary safety outcome was androgenisation. Serum gestrinone was quantified by liquid chromatography-tandem mass spectrometry. This study was registered at ClinicalTrials.gov, NCT05570786.Findings: From February 2023 to November 2024, 100 women with endometriosis-related pain who had previously undergone surgery were enrolled and followed, with an optional 24-week open-label pharmacokinetic extension (n=15). No treatment-related serious adverse event was reported. The incidence of treatment-related adverse events was higher in the gestrinone group than in the placebo group (44% vs 24%, P=0·03), and most events were mild or moderate. At least one sign of androgenisation was reported in 74% of participants in the gestrinone group and 42% in the placebo group (P<0·01). Serum gestrinone levels peaked at week 8 (4·82 ng/mL), declined after week 16, and showed a profile influenced by prior implant use. Gestrinone’s pharmacokinetic profile was characterised by a Tmax of 1131 hours and a half-life of 1491 hours with a Cmax of 6·5 ng/mL. Interpretation: The use of an 85-mg gestrinone bioabsorbable implant combined with a levonorgestrel-releasing intrauterine system is safe and well-tolerated, supporting the clinical feasibility of this therapy for endometriosis.

  • Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)

    by Rebeca Higino Becker, Roberto Augusto Caffaro, Caroline Cândida Carvalho de Oliveira, Rafaela Palermo Marcondes, Ariadne Ribeiro Negrão, Flávia Magella, Giuliano Giova Volpiani, Samantha Neves, Renata Camila Barros Rodrigues, Mariana Ferreira Borges Firmo Rodrigues, et al.

    Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.

  • Open Access

    Biomarker Analysis from the Compass Claudication Study – Rivaroxaban for Intermittent Claudication

    by Karen Falcão Britto, Roberto Augusto Caffaro, Giuliano Giova Volpiani, Maria Fernanda Portugal, Samantha Neves, Alexia Paganotti, Felipe Menegueti Pereira, Leandro Barile Agati, Camilla M. Ribeiro, Viviane Santana da Silva, et al.

    Introduction: A prospective, randomized, multicenter study compared rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily against aspirin 100 mg once daily alone in patients with peripheral artery disease and intermittent claudication. The study demonstrated that rivaroxaban plus aspirin improved total walking distance. A better comprehension of coagulation and inflammatory biomarkers could serve as a prognostic indicator and inform clinical decision-making. Methods: This is a subsequent biomarker analysis, including 36 patients from both arms and plasma from healthy controls. We used human plasma for comparison purposes of the baseline biomarkers for normality testing. Plasma levels of biomarkers relating to coagulation activation (DD, vWF, thrombin generation potential (TGP), fibrinolysis (PAI-1, TAFI) and inflammation (CRP) were assessed at baseline (day 0) and measured after 24 weeks. Results: Samples from 16 patients allocated to the aspirin plus rivaroxaban group and 20 from the aspirin alone group were collected. No significant differences were observed in biomarkers between patients receiving rivaroxaban plus aspirin and those receiving aspirin alone. Conclusion: There were no differences in coagulation or inflammatory biomarkers in patients with intermittent claudication treated with either rivaroxaban plus aspirin or aspirin alone.

  • Open Access

    Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain

    by André Malavasi, Camilla Moreira Ribeiro, Leandro Barile Agati, Agnaldo Silva Filho, Charles Berger, Eduardo Schor, Ana Comin, Eduardo José Bezerra Neto, Taís Helena de Oliveira, Polyana Raposo Caldas, et al.

    Pelvic pain secondary to endometriosis is a disabling condition. There are multiple treatments available, with variable endpoints. No prospective controlled studies were carried out evaluating subdermal pellets of gestrinone in this population. One hundred participants with documented deep infiltrative endometriosis who underwent surgery without satisfactory response will be randomly assigned (1:1) to either gestrinone 85 mg subdermal bioabsorbable pellets or placebo. Both arms will receive levonorgestrel-releasing intrauterine system (LNG-IUS 12). The treatment duration will be 6 months, with baseline, 3 months and 6 months clinical visits. The primary endpoint is a combination of serious adverse events (SAEs) accumulated within 6 months of insertion of the gestrinone or placebo pellet and collected through spontaneous reports and clinical findings. They include death, threat or risk to life, need for hospitalization, prolongation of pre-existing hospitalization, permanent disability or damage, congenital anomaly; or significant medical occurrences such as venous thromboembolism. The primary safety outcome will be the percentage of patients who do not experience SAEs 6 months after randomization. Androgenization, changes in laboratory exams and in pelvic pain intensity as well as quality of life (SF-36 and EHP-30 questionnaires) will be further evaluated. Daily data on uterine bleeding patterns and the use of pain relief medication will be remotely collected using an App. Pharmacokinetics profile of gestrinone pellet will be characterized. This is the first multicenter randomized controlled trial to evaluate the safety, tolerability and pharmacokinetics profile of subdermal gestrinone pellets and might inform clinical practice for treating these patients. GLADE trial is registered at ClinicalTrials.gov (NCT05570786). This is an investigator-initiated research supported by Biòs Farmacêutica.


  • Open Access

    Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial

    by T.P. Costa, M. Aoki, C.M. Ribeiro, E. Socca, L. Itinose, R. Basso, L. Blanes

    The COVID-19 pandemic has driven the search for alternative therapies, including convalescent plasma, historically used in infectious diseases. Despite results in other diseases, its effectiveness against COVID-19 remains uncertain with conflicting results in clinical trials. A pragmatic, single-center, prospective, and open randomized controlled trial was carried out in a hospital in Brazil, with the aim of evaluating the impact of convalescent plasma on the clinical improvement of patients hospitalized with COVID-19. The World Health Organization (WHO) ordinal scale was used to measure clinical improvement, focusing on the reduction in disease severity by up to 2 points, while antibody and C-reactive protein levels were monitored over time. After hospital admission, participants were randomized 1:1 to receive convalescent plasma and standard treatment or to be part of the control group with standard treatment. Follow-up was carried out on days 1, 3, 7, 14 and/or at discharge. From January 14 to April 4, 2022, 38 patients were included, but 3 were excluded due to protocol deviations, resulting in a total of 35 patients: 19 in the control group and 16 in the plasma group. There was no significant difference in clinical improvement between the convalescent plasma group and the control group, nor in secondary outcomes. The study had limitations due to the small number of patients and limited representation of COVID-19 cases. Broader investigations are needed to integrate therapies into medical protocols, both for COVID-19 and other diseases. Conducting randomized studies is challenging due to the complexity of medical conditions and the variety of treatments available.


  • Open Access

    Lipopolysaccharide and lipotheicoic acid differentially modulate epididymal cytokine and chemokine profiles and sperm parameters in experimental acute epididymitis

    by Erick J. R. Silva, Camilla M. Ribeiro, André F. M. Mirim, Alan A. S. Silva, Renata M. Romano, Jorge Hallak, Maria Christina W. Avellar

    Bacterial infections are the most prevalent etiological factors of epididymitis, a commonly diagnosed inflammatory disease in the investigation of male infertility factors. The influence of early pathogenic mechanisms at play during bacterial epididymitis on reproductive outcomes is little understood. We report here that experimental epididymitis induced in rats by Gram-negative (LPS) and Gram-positive (LTA) bacterial products resulted in differential patterns of acute inflammation in the cauda epididymis. LPS elicited a strong inflammatory reaction, as reflected by upregulation of levels of mRNA for seven inflammatory mediators (Il1b, Tnf, Il6, Ifng, Il10, Nos2 and Nfkbia), and tissue concentration of six cytokines/chemokines (IL1A, IL1B, IL6, IL10, CXCL2 and CCL2) within the first 24 h post-treatment. Conversely, LTA induced downregulation of one (Nfkbia) and upregulation of six (Il1b, Il6, Nos2, Il4Il10 and Ptgs1) inflammatory gene transcripts, whereas increased the tissue concentration of three cytokines/chemokines (IL10, CXCL2 and CCL2). The stronger acute inflammatory response induced by LPS correlated with a reduction of epididymal sperm count and transit time that occurred at 1, 7, and 15 days post-treatment. Our study provides evidence that early epididymal inflammatory signaling events to bacterial activators of innate immunity may contribute to the detrimental effects of epididymitis upon male fertility.